Postdiagnosis physical activity is associated with a lower risk of disease recurrence among survivors of colon cancer. Thirty-nine stage I to III survivors of colon cancer were randomized to usual-care control, 150 minutes per week, or 300 minutes per week of aerobic exercise for 6 months. Exercise was feasible, well-tolerated, and elicited changes in physiologic markers associated with disease recurrence. This study informs future phase II/ III trials. Background: Observational studies suggest that higher volumes of physical activity are associated with a lower risk of disease recurrence among survivors of colon cancer. However, the feasibility and safety of prescribing higher volumes of physical activity to survivors of colon cancer are unknown. Furthermore, the pathways through which exercise may reduce disease recurrence are unknown. Patients and Methods: Survivors of stage I to III colon cancer were randomized to usual-care control, 150 minutes per week of aerobic exercise (low-dose), or 300 minutes per week of aerobic exercise (high-dose). Changes in soluble intercellular adhesion molecule-1 and vascular adhesion molecule-1 prognostic biomarkers were examined. Results: From January 2015 to February 2016, 39 patients were enrolled (n ¼ 13 usual-care control; n ¼ 14 low-dose; n ¼ 12 high-dose), and 38 participants completed the study (97% followup). Over 6 months, the low-dose group completed 142 minutes per week (92.8% adherence), and the high-dose group completed 247 minutes per week (89.0% adherence) of exercise. Compared with the control group, changes in soluble intercellular adhesion molecule-1 were À134.9 ng/mL (95% confidence interval, À238.1 to À31.6 ng/mL) in the low-dose group and À114.8 ng/mL (95% confidence interval, À222.5 to À7.1 ng/mL) in the high-dose group (linear P trend ¼ .023; nonlinear P trend ¼ .044). No changes were observed for soluable vascular adhesion molecule-1 (linear P trend ¼ .791; nonlinear P trend ¼ .604). Non-serious adverse events occurred at similar rates among randomized groups. No serious adverse events occurred. Conclusion: Higher volumes of moderate-intensity aerobic exercise, up to 300 minutes per week, are feasible, safe, and elicit favorable changes in prognostic biomarkers among patients recently treated for stage I to III colon cancer. These data can be used to guide clinical recommendations for patients, and inform future trials.
Introduction
Approximately 1 million people are diagnosed with colon cancer each year worldwide. 1 Three-quarters of patients are diagnosed with disease that is localized to the primary site (stage I-II) or spread to regional lymph nodes (stage III). Despite surgical resection, either alone or in combination with adjuvant chemotherapy, 5-year disease recurrence rates for stage I, II, and III colon cancer are 10%, 20%, and 30% to 50%, respectively. [2] [3] [4] Consequently, there exists a need to identify additional adjuvant therapies that reduce the risk of recurrent disease in this population. The prescription of physical activity or exercise is a potential adjuvant therapy that has been reported by prospective cohort studies to be associated with a reduction in the risk of recurrence and death among colon cancer survivors. [5] [6] [7] The relationship between physical activity and disease outcomes is independent of known prognostic factors, and occurs in a dose-response fashion, 8 such that larger volumes of physical activity or exercise, up to 300 minutes per week, are associated with a lower risk of recurrence and premature mortality. [5] [6] [7] However, it is unknown if doses of exercise as large as 300 minutes per week are behaviorally feasible and have tolerable safety profiles for survivors of colon cancer when compared with smaller doses of exercise, such as 150 minutes per week as is currently recommended by various professional organizations including the National Comprehensive Cancer Network. [9] [10] [11] The FITT-VP principle is the cornerstone of exercise prescription by specifying the frequency, intensity, time, type, volume, and progression of exercise that is appropriate to achieve a desired health outcome. 12 Prior trials of exercise among survivors of colon cancer have not fully described FITT-VP principles, which may limit the specificity of guidance that oncology providers can offer to patients. 13 In addition, the safety profile of exercise among survivors of colon cancer has not been characterized. 14 These limitations may hinder the prescription of exercise as an adjuvant therapy in clinical practice. 15 Furthermore, the biological pathways through which exercise may reduce the risk of disease recurrence and premature mortality among survivors of colon cancer are unknown. Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular adhesion molecule-1 (sVCAM-1) are endothelial cell-adhesion molecules that promote the growth of existing micro-metastases and the formation of new micro-metastases. 16 Concentrations of sICAM-1 and sVCAM-1 increase with disease stage, 17, 18 and elevated concentrations of sICAM-1 and sVCAM-1 are independently associated with disease recurrence and premature death among survivors of colon cancer. [17] [18] [19] [20] [21] sICAM-1 and sVCAM-1 have been recommended as therapeutic targets 22, 23 and represent novel pathways through which exercise may reduce the risk of disease recurrence among survivors of colon cancer. The COURAGE trial was a randomized controlled trial with the primary objectives to test the feasibility, safety, and biological efficacy of 2 distinct doses of aerobic exercise compared with a usual-care control group among patients with stage I to III colon cancer. 24 Our primary hypotheses were that both doses of exercise would be feasible and safe, and that exercise would induce dosedependent improvements in sICAM-1 and sVCAM-1.
Materials and Methods

Study Design and Patients
The COURAGE trial was a single-center, phase II, randomized, 3-arm dose-response exercise trial. Detailed methods for the COURAGE trial have been published. 24 Patients were eligible if they were diagnosed with stage I to III colon cancer; completed surgical resection and adjuvant chemotherapy within 36 months of entering the study; self-reported < 150 minutes per week of moderate or vigorous intensity physical activity using the Paffenbarger Physical Activity Questionnaire
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; age ! 18 years; provided written physician approval; had no additional surgery planned within the 6-month intervention period; and had the ability to walk unaided for 6 minutes. Patients were ineligible if they had a history of another primary cancer (other than nonmelanoma skin cancer); had evidence of distant metastatic disease; were pregnant or breast feeding; were unable to provide a baseline blood sample; had a myocardial infarction or coronary revascularization procedure within the past 3 months; had uncontrolled hypertension; had highrisk or uncontrolled cardiac arrhythmias; had clinically significant heart valve disease; had decompensated heart failure; had a known aortic aneurysm; or had any other condition which, in the opinion of the investigator, may impede testing of study hypotheses or make it unsafe to engage in the exercise program. All participants provided written informed consent.
Randomization and Blinding
Participants were randomly allocated to 1 of 3 groups: usual-care control, low-dose aerobic exercise (150 minutes per week), or highdose aerobic exercise (300 minutes per week). Randomization was stratified by cancer stage. Participants were not blinded to treatment assignment. Outcome measures were obtained by assessors blinded to treatment assignment.
Exercise Treatment Plan
Aerobic exercise was performed for 6 months using studyprovided in-home treadmills (LifeSpan Fitness, TR1200i, Salt Lake City, UT). Participants were provided with a heart rate monitor to objectively record heart rate during each exercise session (Polar Electro Inc, RS400, Lake Success, NY). The heart rate monitors had sufficient memory to record 8 to 12 weeks of exercise using a 1-minute epoch. Participants also completed exercise logs to record the date, time, average heart rate, and exercise duration. Participants met with a clinical exercise physiologist to introduce the exercise prescription, and familiarize the participant with use of the treadmill, completion of exercise logs, use of the heart rate monitor, appropriate warm-up and cool-down, stretches, and proper footwear for aerobic exercise. Participants were encouraged to individualize their frequency (days per week), fractionation (sessions per day), and duration (minutes per session) of exercise according to a schedule that promoted a high level of adherence to the prescribed exercise volume. The exercise physiologist provided ongoing behavioral and clinical support and monitored exercise adherence throughout the duration of the study with the use of weekly telephone and email communications. Exercise intensity was prescribed at 50% to 70% of the age-predicted maximum heart rate. The low-dose and highdose groups progressed towards of the goal of 150 or 300 minutes per week of exercise, respectively. Details of the exercise prescription have been published. 24 The study outcome of exercise feasibility was operationalized as the average weekly adherence to the prescribed exercise dose, defined using the completed number of minutes divided by the prescribed number of minutes. 24 The
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outcome was capped at 100% each week to prevent the overestimation of exercise adherence. Participants randomized into the usual-care control group were asked to maintain their prestudy levels of physical activity and follow the recommendations provided by their physician. After completing 6-month measures, control group participants were provided with an in-home treadmill and individualized exercise program, similar to that prescribed to the 2 exercise groups. Upon study completion, all participants were allowed to keep their studyprovided treadmills.
Measurements
Demographic characteristics were self-reported. Smoking status was obtained from a standardized questionnaire. 26 Caloric intake was quantified using 3-day food records. Moderate to vigorous intensity physical activity was quantified using an accelerometer (ActiGraph GT3Xþ). 27 Functional status was quantified using the 6-minute walk test. 28 Body mass index (kg/m 2 ) was calculated using height (m) and weight (kg). Clinical information including cancer stage, treatment with chemotherapy, and performance status were obtained from cancer registry reports, pathology reports, or (18) 1 (8) 4 (29) 2 (17) Some college 8 (20) 3 (23) 2 (14) 3 (25) College degree or more 24 (62) Exercise and Colon Cancer physician records. Comorbid health conditions were assessed using a self-reported questionnaire and physician records. Five-year predicted overall survival was calculated using a validated nomogram. 29 All participants underwent a fasting blood draw at baseline and 6 months. EDTA-preserved plasma was stored at À80 C. Concentrations of sICAM-1 and sVCAM-1 were quantified using an enzyme-linked immunosorbent assay (EMD Millipore, Bellerica, MA). Baseline and 6-month plasma samples were assayed simultaneously and in duplicate at the end of the study. The coefficients of variation for the sICAM-1 and sVCAM-1 assays were 9.4% and 4.3%, respectively. Participants in all study groups were asked each week by the study coordinator via telephone or email about incident adverse events. All adverse events were graded using the Common Terminology Criteria for Adverse Events, version 4.0. 30 
Statistical Analysis
Categorical baseline characteristics were compared among the 3 groups using the Fisher exact test, and continuous baseline characteristics were compared among the 3 study groups using the Kruskal-Wallis test. Based on prior studies (described elsewhere in detail), 24 against the hypothesis of a dose-response relationship, 39 participants provided 80% power for 2 tests for trend (1 for sICAM-1 and 1 for sVCAM-1), each tested at a type I error rate of 0.025, to maintain the experiment-wise overall error rate of 
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Clinical Colorectal Cancer March 2018 -35 0.05 for the 2 biological endpoints. All inferential analyses were conducted on an intention-to-treat basis. sICAM-1 and sVCAM-1 concentrations were log-transformed in the inferential analysis to improve normality and back-transformed to facilitate interpretation. Changes in outcomes were evaluated from baseline to 6 months among the 3 groups using repeated-measures mixed-effects regression models. This statistical approach includes all available data and accounts for the correlation between repeated measures. The baseline value of the dependent variable and cancer stage (randomization stratification factor) were included as covariates in the regression models. 31 Group-by-time interaction terms were estimated as fixed effects. Results from the regression models are presented as least-square means AE standard error or 95% confidence interval (CI). To evaluate the presence of a doseresponse relationship across randomized groups, a test for trend was conducted by examining linear and nonlinear (quadratic) contrasts.
Results
Between January 2015 and August 2015, 39 survivors of colon cancer were recruited and randomized with data collection ending in February 2016. Baseline characteristics of study participants are (10) 1 (8) 1 (7) 2 (17) Gastroesophageal reflux disease 2 (5) 1 (8) 1 (7) (10) 1 (8) 1 (7) 2 (17) presented in Table 1 . Figure 1 shows the flow of the 39 randomized participants through the study. One participant was lost to followup (97% follow-up rate). Exercise prescription program variables are presented in Table 2 . Over 6 months, including the dose-titration period, the average exercise volume in the low-dose and high-dose groups were 141.5 minutes per week (95% CI, 122.0-160.9) and 247.2 minutes per week (95% CI, 226.2-268.2), respectively (P < .001) (Figure 2 ). Excluding the period during which the exercise dose was being titrated, the average exercise volume in the low-dose and high-dose groups were 153.3 minutes per week (95% CI, 133.4-173.7) and 271.3 minutes per week (95% CI, 249.6-293.1), respectively (P < .001). Over 6 months, adherence to the prescribed volumes of exercise in the low-dose and high-dose groups were 92.8% (95% CI, 88.0%-97.6%) and 89.0% (95% CI, 83.8%-94.2%), respectively (P ¼ .287). The high-dose group exercised on more days per week (P ¼ .001), more sessions per day (P ¼ .001), longer duration per session (P < .001), and required more weeks to progress to the full dose of prescribed exercise (P ¼ .007), as compared with the lowdose group. Exercise intensity was 70.7% (95% CI, 69.0%-72.4%) of the age-predicted maximal heart rate, the proportion of exercise sessions using the study-provided treadmill was 76.5% (95% CI, 58.2%-94.9%), and the proportion of exercise sessions validated with objective heart rate data was 96.8% (95% CI, 95.6%-98.0%), all of which did not differ between the 2 exercise groups. Compared with the control group, over 6 months, accelerometer-quantified moderate to vigorous intensity physical activity increased by 22.3 minutes per day (95% CI, 4.7-39.8) in the low-dose group, and 28.8 minutes per day (95% CI, 10.8-47.0) in the high-dose group, respectively (P trend < .001). Compared with the control group, over 6 months, the distance walked in 6 minutes increased by 11.4 m (95% CI, À24.4 to 47.2) in the low-dose group, and 40.9 m (95% CI, 3.7-78.1) in the high-dose group, respectively (P trend ¼ .002).
Endothelial cell-adhesion outcomes are presented in Table 3 . At baseline, no differences among the 3 groups were observed for sICAM-1 (P ¼ .180) and sVCAM-1 (P ¼ .148). Exercise reduced sICAM-1 in dose-response fashion (linear P trend ¼ .023; nonlinear P trend ¼ .044). Compared with the control group, over 6 months, sICAM-1 decreased 134.9 ng/mL (95% CI, À238.1 to À31.6) in the low-dose group, and 114.8 ng/mL (95% CI, À222.5 to À7.1) in the high-dose group. No effects of exercise were seen for sVCAM-1 (linear P trend ¼ .791; nonlinear P trend ¼ .604).
Adverse events are presented in Table 4 . Common nonserious (grade 1-2) adverse events included arthralgia (n ¼ 16; 42%), back pain (n ¼ 12; 31%), generalized flu-like symptoms (n ¼ 8; 21%), foot blisters (n ¼ 7; 18%), and myalgia (n ¼ 6; 16%). The anatomical sites of arthralgia included the knees (n ¼ 8; 50%), ankles (n ¼ 5; 31%), hips (n ¼ 2; 13%), and shoulders (n ¼ 1; 6%). The anatomical sites of myalgia included the feet (n ¼ 4; 67%) and calves (n ¼ 2; 33%). No serious (grade ! 3) adverse events occurred.
Discussion
Our data indicate that survivors of colon cancer are able to complete high volumes (300 minutes per week) of aerobic exercise. To our knowledge, 300 minutes per week is the largest volume of exercise that has been prescribed in this population. Both 150 and 300 minutes per week doses of exercise elicited physiologic effects on sICAM-1, a prognostic biomarker and potential biological mediator of the effects of exercise in this population. Exercise was well-tolerated. No serious (grade ! 3) adverse events occurred, and the profile of nonserious (grade 1-2) adverse events is consistent with what would be expected with exercise: arthralgia, myalgia, back pain, and foot blisters, which can be mitigated with appropriate warm-up and cool down, proper progression of exercise, and consultation with an exercise physiologist to tailor the prescribed exercise dose in response to adverse events. These data can be used to guide clinical recommendations for patients, and inform future phase II and III trials.
The biological pathways through which exercise may reduce the risk for disease recurrence and premature mortality have not been (7) 1 (8) a Data are N (%).
Exercise and Colon Cancer elucidated. Endothelial cell-adhesion molecules, including sICAM-1 and sVCAM-1, have emerged as therapeutic targets, 22, 23 given their implication in promoting the growth of existing micro-metastases and the formation of new micro-metastases through circulating tumor cell differentiation, cell-cell adhesion, and dissemination via activation of the PI3K-Akt-mTOR pathway. 16 We hypothesized that exercise would reduce sICAM-1 and sVCAM-1. Our hypothesis was supported, in part, as both doses of exercise produced significant reductions in sICAM-1, but not in sVCAM-1. It is not clear why sVCAM-1 was not reduced with exercise. These data are consistent with the hypothesis that sICAM-1 may be involved in the anticancer effects of exercise. Our findings build upon prior studies among survivors of colon cancer that have demonstrated that exercise favorably alters oxidative DNA damage and immune parameters.
14 There are several limitations to this trial. The main limitation is the small sample size, which limits the generalizability of our findings. We have reported that trial participants were younger than the population from which they were recruited, 24 which may help oncology providers to circumscribe the patient population these findings may be applicable. The exercise intervention was 6 months, which limits our ability to understand if survivors of colon cancer are able to sustain the observed changes in behavior over longer periods such as 24 or 36 months. There are several strengths to this trial. The use of 2 distinct doses of exercise is novel in this setting, and allowed us to understand the feasibility, safety, and physiologic effects along the exercise dose curve. Exercise adherence was excellent in both groups, which is likely a result of providing in-home treadmills, allowing participants to individualize the exercise prescription according to a schedule of their choosing, and providing regular encounters with an exercise physiologist to deliver behavioral and clinical support. Participants in this trial were more likely to be treated with chemotherapy than the population from which they were recruited, 24 demonstrating the willingness of survivors of colon cancer at high risk for disease recurrence to engage in behavior modification practices. Participants were racially diverse, with 20% of the study sample reporting nonwhite race. Participants reported a variety of comorbid health conditions that are common among survivors of colon cancer, including hypertension, hyperlipidemia, diabetes, and cardiovascular disease. Endpoint data collection was excellent (97% complete).
Conclusion
The findings from this randomized trial establish the feasibility, safety, and biological efficacy of 150 and 300 minutes per week of moderate-intensity aerobic exercise among patients with stage I to III colon cancer. It is noteworthy that both doses of exercise produced reductions in sICAM-1. Additional research is necessary to understand how exercise intensity may alter biomarker outcomes in this population. The findings from this randomized trial are useful to clinical researchers to begin to understand the biologic pathways that are hypothesized to mediate the relationship between exercise and disease recurrence in this population. The findings from this randomized trial may also be useful to oncology providers to improve the specificity of exercise prescriptions, delineate the risk to benefit ratio of prescribing exercise, and promote the prescription of exercise as a potential adjuvant therapy to survivors of colon cancer.
Clinical Practice Points
Prospective cohort studies that demonstrate that participation in physical activity after a diagnosis of stage I to III colon cancer is associated with a 50% lower risk of cancer recurrence and mortality. A consistent finding is that post-diagnosis physical activity is associated with disease outcomes in a dose-response fashion, suggesting that larger volumes of physical activity or exercise, up to approximately 300 minutes per week, are necessary to maximally reduce the risk of disease recurrence and mortality. However, it is unknown if prescribing doses of exercise as large as 300 minutes per week are behaviorally feasible and have tolerable safety profiles for survivors of colon cancer when compared with smaller doses of exercise, such as 150 minutes per week as is currently recommended by various professional organizations. Furthermore, the biological pathways through which exercise may reduce the risk of disease recurrence and mortality among colon cancer survivors are unknown. Thirty-nine survivors of stage I to III colon cancer were randomized to usual-care control, 150 minutes per week of aerobic exercise (low-dose), or 300 minutes per week of aerobic exercise (high-dose). Both intervention groups maintained excellent adherence to the exercise program over 6 months: the low-dose group completed 142 minutes per week (92.8% adherence), and the high-dose group completed 247 minutes per week (89.0% adherence). Both doses of exercise lowered sICAM-1, which is a biomarker that has been associated with disease recurrence and mortality. This may partially explain the anti-cancer effects of exercise. Non-serious adverse events occurred at similar rates among randomized groups. These data can be used to guide clinical recommendations for patients, and inform future trials.
